Sanara MedTech has stopped being a standalone surgical-growth story and has become a merger stub. MiMedx Group agreed in late July to buy the Fort Worth company for $33 in cash plus a fixed fraction of a MiMedx share. The parties marketed that mix as a $35 package at a large premium to the pre-deal tape. The cash piece is the floor. The stub is residual exposure to the buyer's own equity. The investment question is no longer whether the collagen franchise keeps compounding inside a thin public vehicle. It is whether the stockholder vote, the antitrust clock, and the buyer's committed loan actually deliver that cash before the agreement's long-stop date.
The quarter underneath the deal still matters because it is what a break would send investors back to. Soft-tissue repair, led by CellerateRX Surgical Powder and BIASURGE irrigation, carried almost all of the $28.1 million print. Growth slowed to 9% after a much faster first quarter, and the smaller bone-fusion book slipped. Gross margin stayed extremely high, yet operating income compressed because selling costs and deal-advisory fees outran the top line. Adjusted earnings before interest, taxes, depreciation, and amortization still rose, but only after adding back more than a million of transaction costs. That is a franchise that prints cash at the product level and then spends it on the field force, the CRG term loan, and now the sale process.
Shares now trade near $35, essentially on top of the live package once the MiMedx stub is marked. A break would reopen the standalone debate around a high-nineties gross-margin surgical line and a leveraged term loan that still has a minimum-revenue test this year. The bone-fusion book is already shrinking. Does the stockholder vote and Hart-Scott-Rodino clock convert the cash, or does a failed close drop the equity back toward the mid-twenties tape that existed in July?